Confirmed Control Closed Transaction verified biopharmaceuticalscannabinoid medicinescannabis based epilepsy drugLife Sciences Cannabinoid Medicines
GW Pharmaceuticals acquired by Jazz Pharmaceuticals
Jazz Pharmaceuticals acquired GW Pharmaceuticals, a life sciences cannabinoid medicines brand, on May 5, 2021.
Transaction summary
- Target
- GW Pharmaceuticals
- Acquirer
- Jazz Pharmaceuticals
- Seller
- -
- Announced
- 2021-02-03
- Geography
- -
- Tags
- biopharmaceuticalscannabinoid medicinescannabis based epilepsy drugLife Sciences Cannabinoid Medicines
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-06-19
- Latest update
- 2026-10-21
Value and multiples
100% enterprise value
USD 7.2B
100% enterprise value | USD
Basis: Public source
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
12.9x
EBITDA basis not stated
Basis: FundComb estimate
Basis
- CNBC reported a USD 7.2bn deal, and Jazz Pharmaceuticals completed the acquisition on 5 May 2021. The 12.9x EBITDA multiple comes from FundComb’s comps spreadsheet and is not confirmed by a public source; the EBITDA amount, period and basis behind it are not stated.
Source summary
Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc - PR Newswire
ConfirmedContinue your research
Related transaction comps
biopharmaceuticals
Oyster Point Pharma acquired by Viatris
2022-11-07 · Confirmed
View transaction → biopharmaceuticalsBiohaven Pharmaceutical acquired by Pfizer
2022-05-10 · Confirmed
View transaction → biopharmaceuticalsAimmune Therapeutics acquired by Sociétés des Produits Nestlé S.A. / Nestlé Health Science
2020-08-31 · Estimated
View transaction → biopharmaceuticalsDermira acquired by Eli Lilly
2020-01-10 · Confirmed
View transaction →